Seaport Therapeutics has received an award of up to $15 million to advance its GlyphCele, from the Advanced Research Projects Agency for Health (ARPA-H), in collaboration with the Monash Institute of Pharmaceutical Sciences (MIPS).  GlyphCele is an investigational Glyphed oral prodrug of the COX-2 inhibitor celecoxib, which is designed to target the lymphatic system, reduce […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!